NVCN - ネオバスク (Neovasc Inc.) ネオバスク

 NVCNのチャート


 NVCNの企業情報

symbol NVCN
会社名 Neovasc Inc (ネオバスク)
分野(sector) Health Care   ヘルスケア
産業(industry) Medical/Dental Instruments  
業種    医療関連(Health Care)
概要 事業概要 --   ネオバスクはカナダの医療機器メ―カ―。心臓、血管、および一般外科市場向けに医療機器を開発、製造、販売する。同社が開発中の製品には抵抗性狭心症治療用医療機器「ネオバスク・リデュ―サ―」、および経カテ―テル大動脈弁留置術などに使用される組織加工製品などがある。本社はカナダ・ブリティッシュコロンビア州。   Neovasc, Inc. engages in the development, manufacture and marketing of medical devices. Its focuses on Neovast Tiara, and Neovasc Reducer products. The company was founded on November 2, 2000 and is headquartered in Richmond, Canada.
本社所在地 Suite 5138 - 13562 Maycrest Way Richmond British Columbia V6V 2J7 CAN
代表者氏名
代表者役職名
電話番号
設立年月日 36831
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 110人
url www.neovasc.com
nasdaq_url https://www.nasdaq.com/symbol/nvcn
adr_tso
EBITDA EBITDA ー
終値(lastsale) 2.6315
時価総額(marketcap) 49878745.698
時価総額 時価総額 ―
売上高 売上高 --
企業価値(EV) 企業価値(EV) ー
当期純利益 当期純利益 --
決算概要 決算概要 --

 NVCNのテクニカル分析


 NVCNのニュース

   Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Intercept Pharmaceuticals, Neovasc, Interface, and Biogen and Encourages Investors to Contact the Firm - Stocks News Feed  2020/11/19 02:00:00 Stocks News Feed
NEW YORK, Nov. 18, 2020 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT), Neovasc, Inc. (NASDAQ:NVCN), Interface, Inc. (NASDAQ:TILE), and Biogen, Inc. (NASDAQ:BIIB). Stockholders have until the deadlines below to petition… Read More »Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Intercept Pharmaceuticals, Neovasc, Interface, and Biogen and Encourages Investors to Contact the Firm
   NVCN IMMINENT DEADLINE: Zhang Investor Law Alerts Investors to Deadline in Securities Class Action Lawsuit Against Neovasc Inc. – NVCN - Stocks News Feed  2020/11/17 16:15:00 Stocks News Feed
NEW YORK, Nov. 17, 2020 (GLOBE NEWSWIRE) — Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Neovasc Inc. (NASDAQ: NVCN) between November 1, 2019 and October 27, 2020, inclusive (the “Class Period”). To join the class action, go to http://zhanginvestorlaw.com/join-action-form/?slug=neovasc-inc&id=2476 or call Sophie Zhang, Esq. toll-free at 800-991-3756… Read More »NVCN IMMINENT DEADLINE: Zhang Investor Law Alerts Investors to Deadline in Securities Class Action Lawsuit Against Neovasc Inc. – NVCN
   SHAREHOLDER DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against Neovasc Inc.– NVCN; IMPORTANT DEADLINE-NVCN - Stocks News Feed  2020/11/16 18:46:00 Stocks News Feed
NEW YORK, Nov. 16, 2020 (GLOBE NEWSWIRE) — Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Neovasc Inc. (NASDAQ: NVCN) from November 1, 2019 through October 27, 2020, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Neovasc Inc. investors under… Read More »SHAREHOLDER DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against Neovasc Inc.– NVCN; IMPORTANT DEADLINE-NVCN
   The Daily Biotech Pulse: Urovant In M&A Deal, Sanofi's Binary Event, Conference Presentations  2020/11/13 12:40:10 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 12) ALX Oncology Holdings Inc (NASDAQ: ALXO ) Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Denali Therapeutics Inc (NASDAQ: DNLI ) Eidos Therapeutics Inc (NASDAQ: EIDX ) Fate Therapeutics Inc (NASDAQ: FATE ) Five Prime Therapeutics Inc (NASDAQ: FPRX ) (announced preclinical data supporting evaluation of FPA157 as a novel immunomodulator with the potential to remove Treg-mediated immune suppression in solid tumors) Generation Bio Co (NASDAQ: GBIO ) Guardant Health Inc (NASDAQ: GH ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) Inspire Medical Systems Inc (NYSE: INSP ) Insulet Corporation (NASDAQ: PODD ) Kodiak Sciences Inc (NASDAQ: KOD ) (announced presentation of clinical study data on its investigational therapy KSI-301 in retinal disorders) Kura Oncology Inc (NASDAQ: KURA ) MannKind Corporation (NASDAQ: MNKD ) Myokardia Inc (NASDAQ: MYOK ) Ocular Therapeutix Inc (NASDAQ: OCUL ) Oncorus Inc (NASDAQ: ONCR ) OncoSec Medical Inc (NASDAQ: ONCS ) Pacific Biosciences of California Inc (NASDAQ: PACB ) Repligen Corporation (NASDAQ: RGEN ) Shockwave Medical Inc (NASDAQ: SWAV ) Spero Therapeutics Inc (NASDAQ: SPRO ) Tcr2 Therapeutics Inc (NASDAQ: TCRR ) (announced its third-quarter results) Twist Bioscience Corp (NASDAQ: TWST ) Ultragenyx Pharmaceutical Inc (NASDAQ: RARE ) Veracyte Inc (NASDAQ: VCYT ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Nov.
   Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Neovasc Inc. (NVCN) - Stocks News Feed  2020/11/12 16:30:00 Stocks News Feed
BENSALEM, Pa.–(BUSINESS WIRE)–$NVCN #CLASSACTION–Law Offices of Howard G. Smith reminds investors of the upcoming January 5, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ: NVCN) securities between November 1, 2019 and October 27, 2020, inclusive (the “Class… Read More »Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Neovasc Inc. (NVCN)
   The Daily Biotech Pulse: Urovant In M&A Deal, Sanofi's Binary Event, Conference Presentations  2020/11/13 12:40:10 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 12) ALX Oncology Holdings Inc (NASDAQ: ALXO ) Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Denali Therapeutics Inc (NASDAQ: DNLI ) Eidos Therapeutics Inc (NASDAQ: EIDX ) Fate Therapeutics Inc (NASDAQ: FATE ) Five Prime Therapeutics Inc (NASDAQ: FPRX ) (announced preclinical data supporting evaluation of FPA157 as a novel immunomodulator with the potential to remove Treg-mediated immune suppression in solid tumors) Generation Bio Co (NASDAQ: GBIO ) Guardant Health Inc (NASDAQ: GH ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) Inspire Medical Systems Inc (NYSE: INSP ) Insulet Corporation (NASDAQ: PODD ) Kodiak Sciences Inc (NASDAQ: KOD ) (announced presentation of clinical study data on its investigational therapy KSI-301 in retinal disorders) Kura Oncology Inc (NASDAQ: KURA ) MannKind Corporation (NASDAQ: MNKD ) Myokardia Inc (NASDAQ: MYOK ) Ocular Therapeutix Inc (NASDAQ: OCUL ) Oncorus Inc (NASDAQ: ONCR ) OncoSec Medical Inc (NASDAQ: ONCS ) Pacific Biosciences of California Inc (NASDAQ: PACB ) Repligen Corporation (NASDAQ: RGEN ) Shockwave Medical Inc (NASDAQ: SWAV ) Spero Therapeutics Inc (NASDAQ: SPRO ) Tcr2 Therapeutics Inc (NASDAQ: TCRR ) (announced its third-quarter results) Twist Bioscience Corp (NASDAQ: TWST ) Ultragenyx Pharmaceutical Inc (NASDAQ: RARE ) Veracyte Inc (NASDAQ: VCYT ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Nov.
   Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Neovasc Inc. (NVCN) - Stocks News Feed  2020/11/12 16:30:00 Stocks News Feed
BENSALEM, Pa.–(BUSINESS WIRE)–$NVCN #CLASSACTION–Law Offices of Howard G. Smith reminds investors of the upcoming January 5, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ: NVCN) securities between November 1, 2019 and October 27, 2020, inclusive (the “Class… Read More »Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Neovasc Inc. (NVCN)
   Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Raytheon, Intercept Pharmaceuticals, and Neovasc and Encourages Investors to Contact the Firm - Stocks News Feed  2020/11/12 02:00:00 Stocks News Feed
NEW YORK, Nov. 11, 2020 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Raytheon Technologies Corporation (NYSE: RTX), Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), and Neovasc, Inc. (NASDAQ: NVCN). Stockholders have until the deadlines below to… Read More »Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Raytheon, Intercept Pharmaceuticals, and Neovasc and Encourages Investors to Contact the Firm
   ROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Reminds Neovasc Inc. Investors of Important Deadline in Securities Class Action - NVCN  2020/11/11 22:52:00 Benzinga
NEW YORK , Nov. 11, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Neovasc Inc. between November 1, 2019 and October 27, 2020 , inclusive (the "Class Period") of the important January 5, 2021 lead plaintiff deadline in the case. The lawsuit seeks to recover damages for Neovasc investors under the federal securities laws. To join the Neovasc class action, go to http://www.rosenlegal.com/cases-register-1976.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) the results of COSIRA, … Full story available on Benzinga.com
   Peregrine Ventures raises life science fund with USD300m target  2020/11/11 17:28:41 PrivateEquityWire
Peregrine Ventures raises life science fund with USD300m target Submitted By Karin Wasteson | 11/11/2020 - 5:28pm Israeli VC firm Peregrine Ventures has launched its fifth fund and first growth fund, Peregrine Growth, focused on late stage life science companies that are on the verge of an IPO or M&A deal. Peregrine Growth will invest USD20 to USD30 million per round in sectors including medical devices, pharma and digital health. “With the renewed focus on biotech, health, and life science in the wake of the COVID-19 crisis, the potential of Peregrine Growth is great,” says Eyal Lifschitz, managing partner and co-founder at Peregrine Ventures. Several of Peregrine’s current portfolio companies have pivoted to combat Covid-19. For example, Cordio’s noninvasive technology is able to remotely monitor and diagnose the status of COVID-19 patients based on the analysis of their speech pattern. Israeli institutional investors have contributed USD101 million of the planned USD300 million to the fund so far, and Peregrine is aiming to raise additional capital from institutional investors and family offices globally. "Many industry executives are aware that insufficient funds have been invested in healthcare and pharma technologies, and therefore expect that the life science sector will experience significant growth over the next decade.
   Neovasc : Management'sDiscussion and Analysis | MarketScreener  2020/08/06 21:14:04 MarketScreener
Neovasc Inc. Management's Discussion and Analysis FOR THE THREE AND SIX MONTHS ENDED JUNE 30,… | August 6, 2020
   Neovasc Announces Second Quarter Financial Results  2020/08/06 20:05:00 NewMediaWire
VANCOUVER and MINNEAPOLIS - (NewMediaWire) - August 06, 2020 - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, and minimally invasive devices for the treatment of refractory angina, today reported financial results for the second quarter ended June 30, 2020. Second Quarter Highlights Following a COVID-related slowdown, experienced a sharp rebound in Reducer implants in June, meeting pre-COVID monthly Reducer target Confirmed FDA Circulatory Systems Devices Panel Meeting Date of Oct 27, 2020 Advanced CE Mark approval application for transapical Tiara TA mitral valve under Medical Device Directive Conducted further successful animal implants of transfemoral Tiara TF mitral valve replacement system “Cardiovascular diseases did not take a break during the quarter, and neither did Neovasc. We continue to pursue the promise of our novel devices to help patients with limited options for treating debilitating angina, and advancing at the forefront of mitral valve replacement technology,” said Fred Colen, Chief Executive Officer. “We continued to focus on the commercialization of the Reducer in the EU, and were pleased to see a sharp rebound of Reducer implants in June following the postponement of many elective surgical procedures.
   Neovasc : Announces Second Quarter Financial Results | MarketScreener  2020/08/06 18:49:02 MarketScreener
News Release August 6, 2020 Neovasc Announces Second Quarter Financial Results … | August 6, 2020
   Neovasc : Announces Closing of $11.5 MillionRegistered Direct Offering Priced At-The-Market | MarketScreener  2020/06/17 00:13:04 MarketScreener
News Release June 16, 2020 Neovasc Announces Closing of $11.5 Million … | June 17, 2020
   Neovasc : 5 NVC Q1 F20 MDA 200506 FINAL | MarketScreener  2020/05/21 20:48:06 MarketScreener
Neovasc Inc. Management's Discussion and Analysis FOR THE THREE MONTHS ENDED MARCH 31, 2020 AND… | May 21, 2020

 関連キーワード  (― 米国株 ネオバスク NVCN Neovasc Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)